Pretomanid for tuberculosis treatment: an update for clinical purposes

Coronavirus disease (COVID-19) pandemic determined a 10 years-set back in tuberculosis (TB) control programs. Recent advances in available therapies may help recover the time lost. While Linezolid (LZD) and Bedaquiline (BDQ), previously Group D second line drugs (SLDs) for TB, have been relocated to...

Descripción completa

Detalles Bibliográficos
Autores principales: Occhineri, Sara, Matucci, Tommaso, Rindi, Laura, Tiseo, Giusy, Falcone, Marco, Riccardi, Niccolò, Besozzi, Giorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9461242/
https://www.ncbi.nlm.nih.gov/pubmed/36105740
http://dx.doi.org/10.1016/j.crphar.2022.100128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9461242/
https://www.ncbi.nlm.nih.gov/pubmed/36105740
http://dx.doi.org/10.1016/j.crphar.2022.100128

Ejemplares similares